Is Obesity a Problem in New Cystic Fibrosis Treatments?
Nutrients · 14.09.2024 · 16 (18) · 3103
DOI: 10.3390/nu16183103 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nutrients, online erschienen am 14.09.2024. Verfasst von Marta Solís-García und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Neumología, Hospital Universitario La Princesa, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: Cystic Fibrosis, Obesity, Cystic Fibrosis Transmembrane Conductance Regulator, Body Mass Index. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Malnutrition has always been a problem in CF (cystic fibrosis) patients; however, new treatments with CFTR (cystic fibrosis transmembrane conductance regulator protein) modulators have led to weight gain, with some patients at risk of overweight and obesity.
Objective
Our study aimed to analyze the evolution of BMI (body mass index) after one year of treatment with triple therapy and the factors associated with weight gain in CF patients undergoing treatment with triple therapy with CFTR protein modulators (ETI) (elexacaftor/tezacaftor/ivacaftor).
Methods
We conducted a prospective, observational, longitudinal, multicenter study in patients diagnosed with cystic fibrosis, aged 18 years or older, with at least one F508del allele and who underwent ETI therapy for at least one year, from 2020 to 2023. One hundred and eight patients from two cystic fibrosis units in Spain, Princess University Hospital of Madrid (74 patients) and Central University Hospital of Asturias (HUCA) (34 patients), were included. Demographic data, anthropometric data, lung function, and exacerbations were collected, comparing the data in the previous year to the start of therapy with the results after one year of treatment. Multivariant models were developed to account for repeated weight and BMI measurements, using a mixed effects model approach and accounting for possible modifying factors Results: One hundred and eight patients were included in the study, 58 men (53.7%) and 50 women (46.3%) with a mean age of 29.5 ± 9.4 years (18–59). Patient weight and BMI were recorded at baseline and at 3-month intervals during the study period. The weight increased from 59.6 kg to 62.6 kg and BMI increased from 21.9 kg/m2 to 23.0 kg/m2 after one year of treatment (p < 0.0001 for both). The proportion of underweight individuals decreased after one year of ETI therapy, from 9.3% to 1.9%, while the proportion of overweight or obese individuals increased from 8.3% to 22.9 % at the same time (p < 0.001). In relation to exacerbations, there is a significant increase in the number of patients who did not have any exacerbations after one year of treatment, which increased from 10.2% to 46.2% (p < 0.001), while the number of patients who had >4 exacerbations decreased significantly, from 40.7% to 1.9% (p < 0.001). FEV1% (forced expiratory volume) increased from 63.9 ± 20.9 to 76.8 ± 21.4 (p < 0.001) and the VR/TLC (residual volume/total lung capacity) value decreased from 45.1 ± 10.9 to 34.9 ± 6.2 (p < 0.001). The proportion with FEV1% > 80% increased from 23.1% before ETI therapy to 49.1% one year after ETI therapy. We performed multivariate mixed models to evaluate the evolution of BMI changes with time, accounting for repeated measures and for possible modifying factors. After the introduction of the triple therapy, patients included in the study had significant weight gain during the 12 months, and when including different covariates in the multivariate mixed model, we found that lower baseline BMI, lower baseline FEV1 and FVC (forced vital capacity), and higher VR/TLC value and higher number of exacerbations were associated with higher BMI changes over the study period.
Conclusions
CF patients treated with triple therapy experience significant weight gain, increasing the proportion of overweight patients. CF patients who experienced greater weight gain were those with worse BMI at the start of treatment, as well as patients with worse lung function and a greater number of exacerbations in the year before starting ETI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Neumología, Hospital Universitario La Princesa, 28006 Madrid, Spain.
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Universidad de Oviedo, 33011 Oviedo, Spain.
- Servicio de Neumología, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
- Facultad de Ciencias de la Salud-HM Hospitales, Universidad Camilo José Cela, 28014 Madrid, Spain.
ORCID-Profile: Marta María García-Clemente, Adrián Peláez
Zitieren
APA
Solís-García, M., García-Clemente, M. M., Madrid-Carbajal, C. J., Peláez, A., Gómez Punter, R. M., Eiros Bachiller, J. M., & Girón Moreno, R. M. (2024). Is Obesity a Problem in New Cystic Fibrosis Treatments?. Nutrients, 16(18), 3103. https://doi.org/10.3390/nu16183103
Vancouver
Solís-García M, García-Clemente MM, Madrid-Carbajal CJ, Peláez A, Gómez Punter RM, Eiros Bachiller JM, et al. Is Obesity a Problem in New Cystic Fibrosis Treatments?. Nutrients. 2024;16(18):3103. doi:10.3390/nu16183103
BibTeX
@article{SolsGarca2024,
author = {Solís-García, Marta and García-Clemente, Marta María and Madrid-Carbajal, Claudia Janeth and Peláez, Adrián and Gómez Punter, Rosa Mar and Eiros Bachiller, Jose María and Girón Moreno, Rosa María},
title = {Is Obesity a Problem in New Cystic Fibrosis Treatments?},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {18},
pages = {3103},
doi = {10.3390/nu16183103}
}
EUVIMED